COGNITION THERAPEUTICS

0,5189

07-ноября-24 15:29:31

15 мин. задержка

Акции

+0,0191

+3,82%

Сегодняшний диапазон

0,5081 - 0,5301

ISIN

N/A

Источник

NASDAQ

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

31 окт 2024 16:15:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

29 окт 2024 12:55:00 Источник Nasdaq GlobeNewswire
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD

23 окт 2024 07:30:27 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

22 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

02 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

01 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

03 сен 2024 07:30:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

22 авг 2024 07:31:24 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

08 авг 2024 07:00:53 Источник Nasdaq GlobeNewswire
Cognition Therapeutics to Report Second Quarter 2024 Financial Results

05 авг 2024 07:30:19 Источник Nasdaq GlobeNewswire
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients

29 июл 2024 07:00:33 Источник Nasdaq GlobeNewswire
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024

26 июл 2024 16:11:52 Источник Nasdaq GlobeNewswire
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC

02 июл 2024 07:30:38 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

21 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

07 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

29 апр 2024 07:30:57 Источник Nasdaq GlobeNewswire
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease

22 апр 2024 07:30:22 Источник Nasdaq GlobeNewswire
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

02 апр 2024 07:30:47 Источник Nasdaq GlobeNewswire
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024

01 апр 2024 07:30:39 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

26 мар 2024 07:00:56 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.